Media and Entertainment Media and Entertainment

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript


Published on 2025-03-05 00:21:41 - MSN
  Print publication without navigation

  • Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is $-0.29 EPS, expectations were $-0.24. Operator: Good morning, and welcome to the Ocular Therapeutix Fourth Quarter 2024 Earnings Conference Call.

The article provides a transcript of the Q4 2024 earnings call for Ocular Therapeutix Inc., a biopharmaceutical company focused on eye care. During the call, CEO Antony Mattessich and CFO Donald Notman discussed the company's financial performance, operational updates, and future outlook. Key points included the progress of their lead product candidate, OTX-TKI, for the treatment of wet age-related macular degeneration (wet AMD), with positive interim data from the ongoing Phase 1 HELIOS trial. They also touched on the development of other pipeline products, strategic partnerships, and the company's efforts to manage costs while advancing their clinical programs. The call highlighted a focus on innovation in ophthalmic treatments, aiming to address unmet medical needs in eye diseases.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/ocular-therapeutix-inc-nasdaq-ocul-q4-2024-earnings-call-transcript/ar-AA1AdUnD ]